Azkarra Therapeutics
Founded 2007 · 26 employees on LinkedIn · 1 known investors
Azkarra Therapeutics develops small molecule drugs targeting DNA damage repair and immune response pathways for cancer and inflammatory diseases. The company focuses on novel PARP inhibitors, PARG inhibitors, and OGG1 inhibitors as next-generation precision therapeutics.
Founders & leadership
Azkarra Therapeutics was founded in 2007 by Alan Ashworth.
AA
Alan AshworthFounder
Investors · 1
Frequently asked questions
- What does Azkarra Therapeutics do?
- Azkarra Therapeutics develops small molecule drugs targeting DNA damage repair and immune response pathways for cancer and inflammatory diseases. The company focuses on novel PARP inhibitors, PARG inhibitors, and OGG1 inhibitors as next-generation precision therapeutics.
- Who founded Azkarra Therapeutics?
- Azkarra Therapeutics was founded by Alan Ashworth in 2007.
- Who are Azkarra Therapeutics's investors?
- Azkarra Therapeutics's investors include Pandect Bioventures.